Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Promising Pipeline | Explore Protagonist Therapeutics' lead candidates rusfertide and icotrokinra, showing potential in treating polycythemia vera and ulcerative colitis respectively |
Market Potential | Delve into analysts' projections for rusfertide's peak sales of $1.6 billion in the U.S. and icotrokinra's potential to exceed $5 billion globally |
Financial Health | Learn about PTGX's strong financial position with $698 million in cash, providing runway through 2028 and a robust Altman Z-Score of 38.68 |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $50 to $80, reflecting optimism about PTGX's growth potential in the biotech secto |
Metrics to compare | PTGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTGXPeersSector | |
---|---|---|---|---|
P/E Ratio | 69.8x | −2.0x | −0.5x | |
PEG Ratio | −0.96 | −0.08 | 0.00 | |
Price/Book | 5.4x | 2.5x | 2.6x | |
Price / LTM Sales | 17.4x | 8.7x | 3.3x | |
Upside (Analyst Target) | 22.8% | 268.3% | 38.7% | |
Fair Value Upside | Unlock | 16.9% | 5.0% | Unlock |